Tracers / [68Ga]DOTA-KiSS-34
[68Ga]DOTA-KiSS-34
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated KISS1R-targeting peptide (kisspeptin analogue)
- Target / mechanism
- KISS1R (kisspeptin receptor) PMID 41774810
- Clinical application
- Preclinical radiotheranostic (imaging and therapy) tool for KISS1R-positive triple-negative breast cancer PMID 41774810
- Theranostic pair
- <a href="/tracers/lu177-dotakiss34/">lu177-dotakiss34</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | 96.1% to 97.8% | DOTA-KiSS-34 | 41774810 2026 Mol Pharm A 5 \u03bcg (1 \u03bcg/\u03bcL) portion of each DOTA-KP was mixed with 30 \u03bcL of sodium acetate (1.14 M), and 300 \u03bcL of 68GaCl3 (50 MBq) was added. |
Need this precursor?We can point you to suppliers for [68Ga]DOTA-KiSS-34, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41774810. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41774810: 'DOTA-KiSS-34'.